Charles River Laboratories Common Stock Net 2010-2025 | CRL
Charles River Laboratories common stock net from 2010 to 2025. Common stock net can be defined as the value of common equity ownership.
- Charles River Laboratories common stock net for the quarter ending March 31, 2025 was $0.001B, a 0.58% decline year-over-year.
- Charles River Laboratories common stock net for 2024 was $0.001B, a 0.39% decline from 2023.
- Charles River Laboratories common stock net for 2023 was $0.001B, a 0.79% increase from 2022.
- Charles River Laboratories common stock net for 2022 was $0.001B, a 0.79% increase from 2021.
| Charles River Laboratories Annual Common Stock Net (Millions of US $) |
|
|---|---|
| 2024 | $1 |
| 2023 | $1 |
| 2022 | $1 |
| 2021 | $1 |
| 2020 | $0 |
| 2019 | $0 |
| 2018 | $0 |
| 2017 | $1 |
| 2016 | $1 |
| 2015 | $1 |
| 2014 | $1 |
| 2013 | $1 |
| 2012 | $1 |
| 2011 | $1 |
| 2010 | $1 |
| 2009 | $1 |
| Charles River Laboratories Quarterly Common Stock Net (Millions of US $) |
|
|---|---|
| 2025-03-31 | $1 |
| 2024-12-31 | $1 |
| 2024-09-30 | $1 |
| 2024-06-30 | $1 |
| 2024-03-31 | $1 |
| 2023-12-31 | $1 |
| 2023-09-30 | $1 |
| 2023-06-30 | $1 |
| 2023-03-31 | $1 |
| 2022-12-31 | $1 |
| 2022-09-30 | $1 |
| 2022-06-30 | $1 |
| 2022-03-31 | $1 |
| 2021-12-31 | $1 |
| 2021-09-30 | $1 |
| 2021-06-30 | $1 |
| 2021-03-31 | $1 |
| 2020-12-31 | $0 |
| 2020-09-30 | $0 |
| 2020-06-30 | $0 |
| 2020-03-31 | $0 |
| 2019-12-31 | $0 |
| 2019-09-30 | $0 |
| 2019-06-30 | $0 |
| 2019-03-31 | $0 |
| 2018-12-31 | $0 |
| 2018-09-30 | $1 |
| 2018-06-30 | $1 |
| 2018-03-31 | $1 |
| 2017-12-31 | $1 |
| 2017-09-30 | $1 |
| 2017-06-30 | $1 |
| 2017-03-31 | $1 |
| 2016-12-31 | $1 |
| 2016-09-30 | $1 |
| 2016-06-30 | $1 |
| 2016-03-31 | $1 |
| 2015-12-31 | $1 |
| 2015-09-30 | $1 |
| 2015-06-30 | $1 |
| 2015-03-31 | $1 |
| 2014-12-31 | $1 |
| 2014-09-30 | $1 |
| 2014-06-30 | $1 |
| 2014-03-31 | $1 |
| 2013-12-31 | $1 |
| 2013-09-30 | $1 |
| 2013-06-30 | $1 |
| 2013-03-31 | $1 |
| 2012-12-31 | $1 |
| 2012-09-30 | $1 |
| 2012-06-30 | $1 |
| 2012-03-31 | $1 |
| 2011-12-31 | $1 |
| 2011-09-30 | $1 |
| 2011-06-30 | $1 |
| 2011-03-31 | $1 |
| 2010-12-31 | $1 |
| 2010-09-30 | $1 |
| 2010-06-30 | $1 |
| 2010-03-31 | $1 |
| 2009-12-31 | $1 |
| 2009-09-30 | $1 |
| 2009-06-30 | $1 |
| 2009-03-31 | $1 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $6.660B | $4.050B |
| Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $134.174B | 25.17 |
| Elevance Health (ELV) | United States | $86.874B | 11.21 |
| CVS Health (CVS) | United States | $76.179B | 9.47 |
| Cencora (COR) | United States | $56.230B | 19.56 |
| DiDi Global (DIDIY) | China | $23.297B | 35.36 |
| Natera (NTRA) | United States | $20.821B | 0.00 |
| BioMerieux (BMXMF) | France | $15.355B | 0.00 |
| Solventum (SOLV) | United States | $12.571B | 13.31 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $12.522B | 0.00 |
| CochLear (CHEOY) | Australia | $11.391B | 0.00 |
| Revvity (RVTY) | United States | $10.665B | 18.35 |
| ICON (ICLR) | Ireland | $10.255B | 9.53 |
| Viatris (VTRS) | United States | $9.976B | 3.43 |
| Doximity (DOCS) | United States | $9.570B | 44.57 |
| Avantor (AVTR) | United States | $8.763B | 12.73 |
| HealthEquity (HQY) | United States | $8.657B | 42.59 |
| Medpace Holdings (MEDP) | United States | $8.422B | 22.37 |
| Sonic Healthcare (SKHHY) | Australia | $8.157B | 0.00 |
| Amplifon S.p.A (AMFPF) | Italy | $4.966B | 26.21 |
| BrightSpring Health Services (BTSG) | United States | $3.994B | 36.97 |
| Bausch + Lomb (BLCO) | Canada | $3.976B | 23.44 |
| Sotera Health (SHC) | United States | $3.480B | 19.77 |
| Surgery Partners (SGRY) | United States | $2.896B | 37.67 |
| Alignment Healthcare (ALHC) | United States | $2.867B | 0.00 |
| Concentras Parent (CON) | United States | $2.744B | 15.86 |
| Organon (OGN) | United States | $2.259B | 2.40 |
| Ardent Health Partners (ARDT) | United States | $2.117B | 9.02 |
| GeneDx Holdings (WGS) | United States | $1.921B | 73.99 |
| Premier (PINC) | United States | $1.910B | 14.50 |
| Progyny (PGNY) | United States | $1.791B | 39.42 |
| PACS (PACS) | United States | $1.494B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.364B | 27.29 |
| Teladoc Health (TDOC) | United States | $1.211B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.200B | 9.13 |
| Establishment Labs Holdings (ESTA) | $1.066B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $0.998B | 0.00 |
| CareDx (CDNA) | United States | $0.953B | 14.88 |
| Agilon Health (AGL) | United States | $0.911B | 0.00 |
| Nutex Health (NUTX) | United States | $0.901B | 13.61 |
| AMN Healthcare Services Inc (AMN) | United States | $0.830B | 7.77 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| Embecta (EMBC) | United States | $0.614B | 4.14 |
| InnovAge Holding (INNV) | United States | $0.543B | 0.00 |
| LifeMD (LFMD) | United States | $0.523B | 0.00 |
| Enhabit (EHAB) | United States | $0.520B | 42.75 |
| Auna S.A (AUNA) | Luxembourg | $0.505B | 11.37 |
| Sonida Senior Living (SNDA) | United States | $0.465B | 0.00 |
| SBC Medicals (SBC) | United States | $0.398B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.388B | 0.00 |
| Oncology Institute (TOI) | United States | $0.226B | 0.00 |
| Beauty Health (SKIN) | United States | $0.217B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.214B | 0.00 |
| KindlyMD (KDLY) | United States | $0.150B | 0.00 |
| DocGo (DCGO) | United States | $0.137B | 22.33 |
| OncoCyte (OCX) | United States | $0.098B | 0.00 |
| So-Young (SY) | China | $0.088B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.071B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.063B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.057B | 0.00 |
| Biodesix (BDSX) | United States | $0.052B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.040B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.031B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.022B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.013B | 0.00 |
| ModivCare (MODV) | United States | $0.013B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.009B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.004B | 0.00 |
| ISpecimen (ISPC) | United States | $0.003B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |